Try as we might, we can’t cover all the biotech news out there! This week has been intense for biotech finance with multiple deals and fundraisings announced.
- Oxford-based Scancell will use ISA Pharmaceuticals’ technology to manufacture its cancer immunotherapy, Modi-1. Preclinical data shows that ISA’s technology can enhance antitumoral responses elicited by Modi-1 by 10 to 100 fold.
- Swiss Polyphor has licensed its neutrophil-targeting drug for cystic fibrosis, POL6014, to Santhera Pharmaceuticals. The deal could bring Polyphor up to CHF121M (€104M).
- PharmaMar has licensed toxic payloads derived from marine organisms to Seattle Genetics, which plans to incorporate them into its next-generation antibody-drug conjugates (ADCs).
- German ImmunoQure has partnered with French pharma Servier to develop autoantibodies against interferon alpha with applications in autoimmune diseases like lupus erythematosus and Sjögren’s syndrome.
- Biom’Up, a French developer of biodegradable surgical devices, has set a target of €43M for its public offering on the Paris Stock Exchange.
- Mainstay Medical, based in Dublin, has raised €30M to support the development and commercialization of its neurostimulation device to treat chronic low back pain.
- Addex Therapeutics has set a target of CHF40M (€35M) to raise on the SIX Swiss Exchange that will help bring to pivotal clinical trials its treatment to reduce dyskinesia caused by Parkinson’s medication.
- The shares of DBV Technologies went up by 24% on Wednesday after the FDA let it submit an application for its peanut allergy treatment despite having failed to meet expectations in the latest clinical trial.
- Affimed has raised $21.6M (€17M) on the Nasdaq to support its cancer immunotherapies.
Images via Shutterstock